Explorez tous les épisodes du podcast Life Science Insights 360 Podcasts

In this episode, we sit down with Levi S. Lian, CEO and Founder of Raycaster, to explore the critical evolution of document intelligence within the enterprise landscape. Drawing from a background that spans Stanford, Harvard Business School, and a deep-rooted family history in medicine, Levi shares his unique perspective on building AI-driven infrastructure that tackles one of the most persistent bottlenecks in modern business: the unstructured and complex document.

The conversation centers on the shift from traditional OCR and simple automation toward true document reasoning. We examine why scientific and technical documents pose such a significant challenge for legacy systems and how Raycaster is enabling organizations to move beyond mere data extraction to achieve actionable insights. We take a closer look at the strategic hurdles of enterprise AI adoption, discussing the vital balance between rapid product innovation and the rigorous demands of data security, accuracy, and regulatory compliance.

Listeners will gain a masterclass in the future of knowledge work and the ROI of modernizing document-heavy workflows. We discuss Levi’s journey as both a technical founder and an angel investor, offering insights into scaling AI infrastructure, overcoming misconceptions about machine intelligence, and the long-term risks facing industries that remain tethered to manual document processing.

In this episode, we are joined by Dr. Stanley T. Lewis, MD, MPH, Founder and CEO of A28 Therapeutics, to trace his profound transition from physician-scientist to biotech entrepreneur. With a career rooted in translational medicine and clinical development, Dr. Lewis provides an expert perspective on the arduous journey of moving innovation from the laboratory bench to the patient’s bedside. We dive into his mission to redefine precision oncology through Targeted Oncolytic Peptides (TOPs)—a novel modality designed to treat cancer with surgical precision while prioritizing the patient’s quality of life.

The conversation explores the strategic and scientific architecture required to build a therapeutics platform from scratch. We examine the lessons learned from Dr. Lewis’s previous success in bringing Trogarzo to market and how those cross-disciplinary insights from virology and infectious diseases are now being applied to solve unmet clinical needs in oncology. We take a closer look at the evolution of A28’s pipeline, discussing how the integration of biomarkers and advanced delivery systems is shaping the next generation of targeted cancer treatments.

Listeners will gain a rare look at the human-centered side of biotech leadership. We discuss the complexities of navigating regulatory milestones and financing, the importance of maintaining scientific rigor under the pressure of patient urgency, and why empathy remains the most critical component of medical innovation. Whether you are a scientist, a founder, or a healthcare leader, this episode offers a roadmap for balancing high-stakes operational execution with a steadfast focus on the human impact of medicine.

In this episode, we sit down with Ganesh Iyer, CEO and Founder of Opprtna Therapeutics and Drug Discovery Partners, to explore the high-stakes world of deep science entrepreneurship. Ganesh shares the personal and professional motivations that led him to tackle some of medicine's most formidable challenges—neurodegeneration and cancer. We delve into the founding vision of Opprtna and its pursuit of a "premium" therapeutics platform that leverages the unique capabilities of aptamers to reach targets once considered undruggable.

The conversation provides a technical yet accessible deep dive into aptamer-based modalities, comparing their precision and flexibility to traditional antibodies and small molecules. We examine the specific hurdles of Central Nervous System (CNS) targeting and the innovative delivery strategies required to cross the blood-brain barrier. Ganesh shares his expertise on translating early-stage preclinical discovery into clinical-ready assets, emphasizing the necessity of scientific rigor and strategic target selection in a competitive biotech landscape.

Listeners will gain a comprehensive look at the business of drug discovery, from navigating complex funding environments to building multidisciplinary teams that can scale. We discuss the balance between maintaining robust in-house capabilities and leveraging external partnerships to accelerate innovation. Whether you are an aspiring scientist-founder or a seasoned industry leader, this episode offers vital insights into the leadership, culture, and breakthroughs defining the next frontier of precision medicine.

In this episode, we sit down with Jodi Barrientos, CEO of Ribbon Bio, to explore how innovation infrastructure is shaping the future of synthetic biology—and why scalable DNA manufacturing is critical to unlocking the next generation of biological breakthroughs.

Jodi shares her journey from bench scientist to biotech entrepreneur, reflecting on the pivotal moments that inspired her to build a deep-tech company at the intersection of science, engineering, and advanced manufacturing. She discusses the founding vision behind Ribbon Bio and the mission to overcome longstanding limitations in traditional DNA synthesis technologies.

At the core of the conversation is the challenge of engineering long, complex, high-fidelity DNA constructs—an essential capability for advancing therapeutics, vaccines, agriculture, and industrial biotechnology. Jodi explains how integrating automation, precision engineering, and computational tools enables a new level of scalability and reliability in synthetic DNA production. By combining advanced manufacturing principles with biological design, Ribbon Bio is building the infrastructure needed to accelerate innovation across the life sciences ecosystem.

We also examine the growing role of computational tools and AI in DNA design—how digital modeling and predictive systems can optimize sequence construction, reduce errors, and streamline development cycles. Jodi highlights the commercialization challenges inherent in deep-tech biotech, from capital intensity to long development timelines, and shares leadership lessons learned while building resilient, highly technical teams.

Episode Highlights:
Ribbon Bio’s approach to redefining synthetic DNA manufacturing
Why scalable innovation infrastructure is critical for biotech growth
How precision, automation, and computational tools transform bioengineering
Insights into leading and scaling a deep-tech company
A forward-looking perspective on programmable biology and its impact across industries

This episode offers valuable insights for biotech founders, synthetic biology innovators, investors, and scientist-entrepreneurs seeking to understand how infrastructure, scale, and precision will define the future of programmable biology.

In this episode, we sit down with Jolly Nanda, Founder and CEO of Altheia, Inc., to explore how artificial intelligence is transforming precision medicine from a reactive model into one that is predictive, personalized, and proactive.

Jolly shares her entrepreneurial journey and the inspiration behind founding Altheia, highlighting the gaps she observed in traditional precision medicine approaches. While precision medicine has made meaningful progress, much of today’s healthcare system still reacts to disease after symptoms appear. Jolly explains how AI-driven insights are changing that paradigm—unlocking deeper understanding from complex patient data, accelerating diagnostics, and enabling earlier, more targeted interventions.

At the core of the conversation is the convergence of AI, clinical data, genomics, and digital health. By integrating multi-omics datasets with real-world clinical information, machine learning models can identify subtle patterns and correlations that would otherwise remain hidden. These insights allow for improved disease prediction, earlier detection, and more individualized therapeutic strategies tailored to each patient’s biological profile.

We also discuss the practical realities of building and scaling AI solutions in healthcare. From regulatory and interoperability challenges to adoption within clinical and commercial environments, Jolly outlines the importance of balancing innovation with trust, transparency, and governance. Responsible AI—grounded in ethical frameworks and robust validation—is essential to ensuring that predictive technologies truly serve patients and providers.

Episode Highlights:
How AI is shifting healthcare from reactive treatment to predictive, preventive care
The power of data-driven personalization in improving patient outcomes
Insights into building and scaling an AI-first precision medicine company
The importance of ethical frameworks, transparency, and responsible AI deployment
A forward-looking vision for AI-enabled, proactive healthcare innovation

This episode offers valuable perspective for healthcare leaders, digital health innovators, biopharma executives, and technologists seeking to understand how AI is reshaping precision medicine—and how predictive intelligence will define the next era of healthcare.

In this episode, we explore how San Diego is evolving as a global innovation hub—and what it will take to shape its next chapter at the convergence of AI, DefenseTech, and Life Sciences.

Long recognized for its strengths in biotech and research institutions, San Diego is now entering a new phase defined by cross-sector collaboration and technological convergence. We examine what differentiates the region from other emerging innovation hubs: a unique blend of research excellence, defense infrastructure, entrepreneurial culture, and global connectivity.

The conversation dives into how ecosystems can effectively support both early-stage startups and established industry leaders. As AI reshapes medtech, biotech, and adjacent sectors, the crossover between technology and life sciences is accelerating—unlocking new models of product development, commercialization, and impact. We discuss how founders can leverage this convergence to build more resilient and scalable companies.

We also address the realities entrepreneurs face today: evolving venture funding dynamics, heightened competition for capital, talent acquisition challenges, and the complexity of global expansion. Founders must move beyond pitching ideas to building investable, execution-ready organizations. Capital strategy now demands clarity, differentiation, and disciplined storytelling that resonates with both investors and customers.

A key theme of the episode is “StoryMaking”—the idea that momentum-driven narratives are more powerful than static origin stories. Translating deep science and complex technology into compelling, forward-looking messages is essential for attracting capital, talent, and partnerships. In a crowded global market, narrative clarity can be as important as technical excellence.

We also reflect on leadership within historic organizations navigating reinvention—how to balance legacy and culture with transformation and growth. Mentorship, long-term perspective, and principled decision-making play critical roles in shaping sustainable innovation ecosystems.

Episode Highlights:
A strategic look at San Diego’s next phase as a global innovation hub
Insights into the convergence of AI, DefenseTech, and Life Sciences
Practical guidance on capital strategy and investor readiness
A fresh perspective on StoryMaking as a driver of ecosystem momentum
Actionable advice for global scaling while maintaining focus and resilience
Leadership reflections on legacy, reinvention, and mentorship
Bold predictions on the future of global innovation ecosystems

This episode is essential listening for founders, investors, operators, and ecosystem builders working to shape not only San Diego’s future—but the broader trajectory of global innovation in the decade ahead.

In this episode, we sit down with Suzanne Vyvoda, Founder and CEO of Concordia BioStrategies, to explore how strategic leadership, operational rigor, and collaborative execution form the foundation of successful biotech companies.

Suzanne shares her journey to becoming a founder, CEO, and trusted strategic partner to emerging biotech organizations. She reflects on the philosophy behind Concordia BioStrategies—rooted in alignment, collaboration, and shared purpose—and why early-stage companies must build strong operational frameworks long before a clinical trial begins.

A central theme of the conversation is the evolving role of the Fractional C-Suite leader. Suzanne explains how this model provides growing biotechs with access to senior-level expertise without the overhead of full-time executive hires. In capital-constrained environments, fractional leadership allows companies to move strategically and efficiently—bringing experienced guidance during critical inflection points while preserving runway.

We dive into why operational excellence must start at the earliest stages of company formation. Too often, companies focus heavily on scientific progress while underestimating the infrastructure required to transition into clinical development. Suzanne outlines common operational pitfalls—from misaligned vendors and unclear governance structures to gaps in quality and compliance—and shares practical frameworks for aligning strategy, operations, and execution.

The conversation also emphasizes balance: how companies can move quickly without sacrificing quality, regulatory discipline, or scientific integrity. Early operational decisions, Suzanne notes, directly influence scalability, investor confidence, and ultimately patient impact. Creating alignment between founders, internal teams, CROs, and external partners is not optional—it is essential.

Episode Highlights:
A founder story grounded in collaboration, clarity, and execution
A clear explanation of the Fractional C-Suite model and its strategic value
Practical guidance on operational readiness before entering the clinic
Real-world insights into avoiding costly clinical-stage missteps
A thoughtful framework for balancing speed, quality, and long-term value creation

This episode is essential listening for biotech founders, emerging executives, and investors seeking to understand how disciplined operations, strategic alignment, and experienced leadership can accelerate the journey from discovery to the clinic—while building resilient companies designed for sustainable growth.

Join us for a powerful and timely episode featuring Golda Naana Boakye, CEO of Naantu, as we examine the urgent need to advance diversity, equity, and inclusion in clinical research. In this compelling conversation, Golda shares why representative clinical trials are not only a matter of social responsibility, but a scientific and clinical imperative essential to improving outcomes for all patients.

We explore the systemic and structural barriers that continue to limit participation from underrepresented communities, from historical mistrust and access challenges to trial design limitations that fail to reflect real-world populations. Golda discusses the importance of rebuilding trust through transparency, meaningful community engagement, and culturally competent communication—shifting clinical research from a transactional model to a patient-centered partnership.

The conversation also highlights how innovative, technology-enabled approaches are helping to remove logistical barriers, expand access, and enhance the participant experience. From decentralized trial models to data-driven outreach strategies, we examine how sponsors and CROs can move beyond intention and toward measurable action in equity-driven research.

Episode Highlights:
A deep dive into why diversity in clinical trials strengthens scientific validity and patient outcomes
Key structural barriers preventing broader participation—and how to address them
The critical role of trust, transparency, and community engagement in recruitment
How digital tools and decentralized models can improve accessibility and inclusivity
Golda’s leadership journey and the mission driving Naantu
Practical strategies for sponsors and research organizations to build more representative trials
A forward-looking vision for patient-centric, equitable clinical research

Whether you're a biopharma executive, clinical researcher, sponsor, or healthcare innovator, this episode offers strategic clarity and actionable insights on building trials that truly reflect the populations they aim to serve. Discover how inclusive research design is shaping the future of medicine—and why equity must be embedded at the core of scientific progress.

Join us for a strategic and deeply insightful episode featuring Ramani Varanasi, Founder and CEO of ReVive Advisors, as we explore the leadership mindset, capital strategy, and decision-making discipline required to build and scale successful biopharma companies. Drawing from his journey from bench scientist to executive leader, entrepreneur, and trusted board advisor, Ramani shares practical lessons shaped by decades of navigating high-stakes environments in biotech.

In this conversation, Ramani reflects on the pivotal moments that shaped his transition into leadership and company-building, offering candid perspectives on balancing bold scientific vision with operational pragmatism. We examine how strong leaders make informed decisions amid uncertainty—particularly during critical clinical, regulatory, and financial inflection points where data may be incomplete and timelines unforgiving.

The discussion dives into patterns Ramani has observed across high-performing biopharma organizations, from aligning scientific ambition with investor expectations to building leadership teams capable of disciplined execution. He shares frameworks for evaluating risk, structuring capital strategy, and making difficult calls when the stakes are high and resources constrained.

We also look ahead to the innovations reshaping the industry—AI, cell and gene therapy, and precision medicine—and explore how these technologies will influence strategy, capital allocation, and patient outcomes over the next decade.

Episode Highlights:
A candid leadership journey from bench science to boardroom influence
Practical insights on fundraising, capital strategy, and company scaling
Clear frameworks for navigating clinical and financial uncertainty
What distinguishes high-performing biotech founders and executive teams
A forward-looking perspective on AI and next-generation biopharma innovation

Whether you're a founder, executive, investor, or aspiring biotech leader, this episode offers strategic clarity and actionable guidance for building resilient organizations in a high-risk, high-reward industry. Discover how disciplined leadership, thoughtful capital strategy, and scientific vision come together to shape the future of biopharma.

In this episode of Life Science 360, we sit down with Dr. Dirk Heckel, Chief Technology Officer of Siemens Healthineers, to explore how technology, informatics, and data-driven innovation are redefining modern diagnostics and transforming clinical laboratories worldwide.

Dr. Heckel shares his unique career journey—rooted in both science and technology—and how this dual foundation has shaped his leadership approach in one of healthcare’s most critical domains. From early inspiration to leading large-scale digital transformation initiatives, he reflects on the power of combining deep scientific expertise with advanced digital platforms to build scalable, impactful healthcare solutions.

At the heart of the conversation is the evolving role of the CTO in diagnostics. Dr. Heckel explains how technology strategy must align closely with clinical realities and patient outcomes—ensuring innovation is not just technically sophisticated, but meaningfully integrated into care delivery. He outlines his vision for the modern clinical laboratory: a connected, intelligent, and data-driven ecosystem where systems are interoperable, workflows are optimized, and data flows seamlessly across platforms.

We explore the evolution of lab informatics over the past decade—from siloed, standalone systems to fully integrated digital environments. Dr. Heckel shares real-world examples of how informatics-driven diagnostics enhance accuracy, reduce turnaround times, and improve operational efficiency. The discussion highlights how intelligent automation, interoperability, and advanced analytics are transforming laboratory data into actionable clinical insights.

Importantly, this transformation is not just about efficiency—it is about impact. By turning laboratory information into timely, clinically relevant intelligence, digital platforms can directly influence patient outcomes, enabling earlier diagnoses, more precise treatments, and better overall care.

Episode Highlights:
A compelling leadership journey blending science, informatics, and executive vision
Clear insights into how digital transformation is reshaping modern diagnostics
A deep dive into the evolution of lab informatics—from systems to connected ecosystems
Practical examples of informatics-driven improvements in accuracy and efficiency
A future-forward vision of intelligent, interoperable, and data-driven laboratories

This episode is essential listening for life science leaders, laboratory professionals, informatics experts, and healthcare innovators navigating the rapidly evolving diagnostics landscape—and seeking to understand how technology and clinical excellence converge to shape the future of healthcare.

Join us for an inspiring episode of Lab Bench to Boardroom: Leading Science-Driven Innovation featuring Ashley Zehnder, CEO of Fauna Bio, as we explore the intersection of bold scientific thinking, biotech leadership, and nature-inspired therapeutics. In this conversation, Ashley shares how Fauna Bio is redefining drug discovery by leveraging multi-omics insights from hibernating species to tackle some of the most complex human diseases.

Ashley reflects on her journey from veterinary science to leading a cutting-edge biotech company, offering candid insights into the challenges and opportunities of women in science and executive leadership. She recounts the founding story of Fauna Bio—sparked by a powerful realization that nature has already solved many biological challenges humans face—and how that “aha” moment evolved into a platform built on evolutionary biology and translational science.

We dive into how Fauna Bio integrates genomics, transcriptomics, and proteomics to uncover protective mechanisms embedded in hibernation biology, and how those insights are translated into potential therapeutics. Ashley also discusses the scientific and operational complexities of working with non-traditional model species, building a science-first culture, and scaling innovation while staying grounded in rigorous data.

Episode Highlights:
A deep exploration of women’s leadership and representation in biotech
Ashley Zehnder’s path from veterinary medicine to biotech CEO
The origin story and vision behind Fauna Bio
How hibernation biology can unlock transformative treatments in human health
Real-world examples of translating animal biology into therapeutic pipelines
Leadership lessons from building and scaling a mission-driven biotech company

Whether you're a scientist, entrepreneur, investor, or innovation leader, this episode offers a compelling look at how evolutionary biology and multi-omics technologies are converging to reshape drug discovery. Discover how science drawn from nature—combined with visionary leadership—can drive the next generation of breakthrough therapeutics.

Join us for an in-depth and thought-provoking episode featuring Alan White, CEO and Co-founder of Arriello, as we explore the evolving world of global regulatory affairs, pharmacovigilance, quality, and compliance—and the powerful intersection of technology and human expertise that is redefining life sciences.

In this conversation, Alan shares his unconventional journey from a commercial career spanning IT, lighting, and translation services into the highly regulated pharmaceutical sector. He reflects on how early exposure to regulatory-driven services inspired him to found Arriello in 2008, during one of the most challenging global financial climates. From building credibility as a new entrant in a trust-based industry to scaling operations across continents, Alan offers a candid look at what it takes to transform a startup into a global organization supporting clients in more than 140 markets.

We dive into Arriello’s evolution from post-marketing regulatory support into a comprehensive strategic advisory partner spanning clinical development, drug safety, and compliance services. Alan unpacks the realities of navigating fragmented global regulatory systems, the importance of local expertise in global market entry, and the common mistakes biotech companies make when expanding internationally. The discussion also explores the growing role of AI and automation in compliance workflows—and why a human-in-the-loop approach remains essential to ensure accuracy, accountability, and sound judgment.

Episode Highlights:
A deep dive into the inspiration and early challenges behind founding Arriello
Insights into building credibility and trust in global regulatory consulting
The transformation from post-marketing support to full-spectrum strategic advisory services
Practical perspectives on integrating AI and automation while preserving human oversight
A forward-looking vision where regulatory affairs and pharmacovigilance become innovation drivers through digital transformation

Whether you're a biotech founder, regulatory professional, or life sciences executive, this episode offers strategic clarity on how compliance, technology, and leadership intersect in today’s global pharmaceutical landscape. Discover how combining digital capability with human expertise is shaping the future of regulatory excellence and accelerating innovation across life sciences.

Join us for a compelling episode featuring the Cofounder and CEO of NyquistAI, a pioneering leader shaping the future of clinical, regulatory, and medical research through artificial intelligence. With a background spanning BCG, Novartis, Google Accelerator, and Stanford, he brings a rare blend of strategic, scientific, and technical expertise to the conversation—offering an inside look at how NyquistAI is redefining the pace of innovation in life sciences.

In this discussion, we uncover how intelligent automation and advanced AI models are enabling organizations to streamline compliance workflows, accelerate research timelines, and dramatically improve the accuracy of clinical and regulatory processes. We explore the vision behind NyquistAI’s platform, the transition from traditional manual operations to data-driven systems, and the measurable impact this transformation is creating across pharma, biotech, and medtech.

You’ll hear real-world examples of how AI is helping teams navigate the complexities of trial design, documentation, and submission, while also reducing bottlenecks that historically slow down drug development and approval. The episode also dives into the practical challenges faced by life science leaders—data standardization, regulatory expectations, and cross-functional collaboration—and how intelligent platforms are starting to solve them at scale.

Episode Highlights:
A deep exploration of AI’s role in modernizing clinical and regulatory research
Insights into how automation accelerates discovery and approval cycles
Real challenges in medical research and how AI-driven solutions overcome them
Forward-looking perspectives on the future of life sciences shaped by intelligent platforms

Whether you're working in pharma, biotech, or medtech, this episode provides a strategic roadmap for harnessing AI to drive speed, precision, and meaningful impact. Get ready to discover how the next generation of digital tools is transforming the path from research to real-world patient outcomes.

In this episode, we sit down with Ome Ogbru, PharmD, CEO and Founder of AINGENS, to explore a career trajectory that spans clinical pharmacy, global medical information leadership, and the cutting edge of AI-driven innovation. We unpack the critical inefficiencies currently plaguing biopharma—from broken workflows to the loss of vital scientific insight—and discuss how Ome’s 20-year journey led to the creation of a platform designed to fix them.

Through this conversation, we examine the shift from solving isolated tasks to addressing entire life sciences workflows end-to-end. We dive into the practicalities of navigating regulatory complexity and shrinking resources, highlighting how AI can act as a force multiplier for research and operational efficiency. Ome shares his perspective on turning career pivots into opportunities for industry-wide transformation, bringing a unique lens on how to communicate complex science through actionable, intelligent solutions.

Listeners will gain a deeper understanding of the intersection between human expertise and machine intelligence in a highly regulated landscape. We discuss the founding of AINGENS as a response to real-world industry hurdles and provide a roadmap for leaders looking to bridge the gap between legacy processes and the future of AI-enabled innovation.

Join us for an immersive exploration into how automation, data intelligence, and predictive analytics are redefining the future of life sciences. In this episode, we unpack the transformative impact of intelligent systems across the entire value chain—from early-stage drug development to complex regulatory and compliance operations that keep global healthcare running safely and efficiently.

Through this conversation, we examine how organizations are integrating AI-driven platforms to streamline research workflows, enhance decision-making, and accelerate time-to-market for critical therapies. We take a closer look at the technologies powering this shift, the strategies teams are using to operationalize advanced analytics, and the measurable outcomes emerging from real-world deployments of automation in clinical and regulatory environments.

Listeners will gain insight into how data-rich systems are not only improving accuracy and reducing risk but also enabling a new era of proactive, predictive healthcare. We discuss case studies highlighting successful AI adoption, the challenges of scaling innovation within highly regulated industries, and the opportunities that arise when scientific rigor meets intelligent automation.

Episode Highlights:
An in-depth look at AI’s expanding role in clinical research and regulatory science
Examples of innovation accelerated by automated, data-driven workflows
Perspectives on the evolution of intelligent healthcare infrastructures and what comes next

Whether you’re a researcher, compliance leader, or technology strategist, this episode offers valuable clarity on how advanced automation is reshaping life sciences globally. Prepare to discover how smarter systems drive smarter decisions—and how that transformation is shaping the future of patient care.

Join us for an engaging episode featuring Rachel Reboulet, Founder and Biotech Ops Partner at Streamline BioOps, as we explore the dynamic and fast-evolving world of life science startups. With extensive experience guiding companies from Seed through Series B, Rachel offers a rare inside look at what it takes to build resilient operations that support scientific ambition and long-term growth.

In this conversation, we uncover how she partners with emerging biotech teams to establish strong operational frameworks, balance scientific priorities with business needs, and create the structures necessary for sustainable scale. Rachel walks us through the realities of early-stage development—from assembling the right team and navigating resource constraints to implementing processes that can evolve alongside the science.

We also discuss the challenges startups face during critical growth phases, including managing cross-functional complexity, preparing for fundraising milestones, and maintaining strategic clarity in rapidly shifting environments. Her journey highlights why operational excellence is not just supportive but foundational to successful biotech innovation.

Episode Highlights:
A deep dive into the core requirements of early-stage biotech success
Insights into designing and scaling operational systems built for growth
Real examples of overcoming Seed-to-Series B hurdles with strategic execution

Whether you’re a founder shaping your first company, an operator refining your systems, or a biotech professional learning the intricacies of building in this sector, this episode delivers practical guidance and strategic perspective. Get ready to understand how operational strategy fuels scientific progress—and why the strongest biotech companies are built on both innovation and disciplined execution.

When artificial intelligence meets healthcare, innovation happens. Join us as we sit down with Jamie Littlejohns, CEO of Velsera, to explore how cutting-edge data strategies are transforming the medical field. From precision medicine to AI-powered diagnostics and the role of real-world data, Jamie shares how Velsera is accelerating the shift toward smarter, patient-centric care.

Expect insights on:

Perfect for listeners interested in healthcare tech, life sciences strategy, and AI’s expanding impact on wellness.

#HealthcareInnovation #DataDrivenHealth #AIinMedicine #Velsera #PrecisionMedicine #Podcast

Join us for an enlightening episode featuring Dr. Amandeep Singh, Ph.D., a seasoned strategy consultant who bridges the worlds of academic research and practical business impact in the life sciences sector.In this conversation, we explore:How Dr. Singh leverages scientific rigor and strategic frameworks to help pharmaceutical and biotech organizations innovate effectively.The process of translating cutting‑edge research into commercial value, from drug discovery to global scale-up.Real-world examples of aligning strategy with execution to accelerate pipeline development and maximize patient impact.Challenges and opportunities in multi-stakeholder decision-making, regulatory navigation, and global commercialization.Dr. Singh’s personal journey: navigating academia, consulting, and strategic leadership in an industry driven by both science and business acumen.Episode Highlights:Deep dive into the intersection of academic excellence and business strategyCase studies illustrating the power of science-informed decision-makingInsight on scaling innovation globally while staying grounded in evidence-based disciplineWhether you're a life sciences professional, industry strategist, or fellow scientist keen on commercializing research, this episode offers actionable insights and strategic clarity.Get ready to learn how scientific excellence meets strategic execution—and how that synergy fuels transformation across pharma and biotech.

Join us for a deep dive into the transformative world of omics with Prabhu Mathiyalagan, CEO of Benthos. In this episode, we explore how multi-omics—genomics, proteomics, metabolomics, and more—are reshaping the future of healthcare and life sciences.Prabhu shares his insights on:The role of omics in driving precision medicine and personalized careBuilding the infrastructure to manage and interpret complex biological dataChallenges in integrating omics into real-world clinical and research settingsThe future of biotech innovation at the intersection of data, biology, and AIHighlights:Making sense of the omics revolutionPractical challenges in turning data into decisionsPrabhu’s journey and vision at the helm of BenthosThis episode is a must-listen for innovators, data scientists, and healthcare leaders navigating the next frontier of life sciences.

In this episode, we speak with Poojan Suri, CEO of Garner BioSolutions, about breaking barriers in biotech. From enabling global access to advancing innovation beyond borders, Poojan shares his vision for a more inclusive life sciences ecosystem. We explore Garner's unique approach to biotech without borders, decentralized R&D, and building collaborations that scale impact across the globe.Topics Covered:Global biotech access and equityInnovation without bordersChallenges in biotech expansionGarner BioSolutions' mission and imp

Join us for an enlightening episode featuring Dr. Leeland Bekstrom, CEO of NashBio, as we explore how real-world data is reshaping the landscape of genomics and precision medicine. With unparalleled insight into large-scale clinical and genomic datasets, Dr. Bekstrom reveals how data-driven discovery is accelerating breakthroughs, enhancing personalized care, and helping bridge critical health equity gaps across diverse populations.

In this conversation, we dive into the transformative power of real-world evidence—how it enables researchers to generate faster, more accurate genomic insights, validate therapeutic targets, and better understand disease progression in ways traditional research alone cannot. Dr. Bekstrom highlights NashBio’s unique role at the intersection of data, research, and patient impact, detailing how the organization is building infrastructure that connects scientific exploration to meaningful real-world outcomes.

We also unpack the complexities of integrating massive datasets, ensuring ethical governance, and scaling platforms that can support next-generation precision health initiatives. From opportunities emerging through data diversity to the challenges of interoperability and privacy, this episode offers a comprehensive look at the evolving future of genomics.

Episode Highlights:
A deep exploration of how real-world evidence accelerates genomic discovery
Insights into the importance of diverse datasets for equitable health outcomes
NashBio’s mission to translate data into measurable patient benefit
Challenges and opportunities in large-scale data integration and scalability
A forward-looking vision for precision medicine powered by comprehensive data ecosystems

Whether you're a clinician, biotech leader, researcher, or simply curious about the next era of health innovation, this episode provides a rare and compelling window into the future of data-driven discovery. Get ready to understand how real-world data is becoming one of the most powerful engines of translational research and personalized medicine.

Join us for a thought-provoking episode featuring Douglas Selinger, Founder and CEO of Plex Research, a visionary leader at the forefront of AI-driven drug discovery and biomedical innovation. In this conversation, we dive deep into how artificial intelligence is reshaping the life sciences landscape- from transforming molecular design to accelerating the journey of a therapy from early discovery to clinical impact.

We unpack how Douglas and his team apply advanced computational models, vast biological datasets, and predictive analytics to streamline R&D workflows for biotech and pharmaceutical organizations. The discussion explores the methodologies behind AI-powered platforms, the transition from algorithmic insights to tangible drug candidates, and the strategic decisions that enable companies to innovate faster and more efficiently.

You’ll hear real-world examples of how data-centric drug development is improving the precision of target identification, reducing costs, and opening new pathways for therapeutic breakthroughs. We also examine the evolving challenges of integrating AI within traditional scientific environments, the complexities of scaling technology across global pharma, and the opportunities emerging at the intersection of biology, computation, and entrepreneurship.

Douglas Selinger’s personal journey—from building scientific foundations to leading a tech-enabled life sciences company—offers a rare perspective on the mindset required to push boundaries in a rapidly advancing industry.

Episode Highlights:
A deep exploration of AI’s growing influence in drug discovery and development
Case-driven insights into how computational approaches are accelerating innovation
A look at the future of medicine shaped by algorithms, automation, and interdisciplinary collaboration

Whether you're a researcher, investor, or industry leader navigating the shift toward digital-first R&D, this episode provides actionable perspectives on how AI is redefining the future of healthcare. Get ready to understand how computational power meets scientific ambition—and how that convergence is transforming biotech, pharma, and patient outcomes worldwide.

Join us for a fascinating episode featuring Mary Siroris, Managing Director of Nordic Global, as we explore how the Nordic region is shaping the future of life sciences, healthcare, and sustainable innovation on the world stage. With her deep experience across global markets, Mary offers an insider’s perspective on the unique Nordic model—one defined by collaboration, purpose-driven leadership, and a commitment to ethical and sustainable progress.

In this conversation, we uncover what truly sets the region apart, from its pioneering public-private partnerships to its culture of trust, transparency, and long-term thinking. Mary walks us through the breakthroughs emerging across biotech, digital health, and rare disease research, and how Nordic organizations are integrating ESG principles not as obligations but as strategic advantages that drive growth and global relevance.

We also explore the expanding vision of Nordic Global, its role in elevating innovation beyond the traditional boundaries of life sciences, and the broader influence the region is having on global policy, technology adoption, and healthcare transformation. Mary shares valuable advice for the next generation of leaders navigating this intersection of science, sustainability, and innovation.

Episode Highlights:
A deep look into the foundational principles powering the Nordic innovation model
Insights into major scientific and digital health breakthroughs emerging from the region
Perspectives on ESG, sustainability, and why they fuel competitive advantage
How Nordic Global is broadening its impact beyond life sciences
Guidance for rising leaders shaping the future of science and technology

Whether you're an innovator, policymaker, or industry strategist, this discussion offers a front-row view into how Nordic leadership is blending purpose, precision, and global ambition to build the industries of tomorrow. Get ready to discover why the world continues to look to the North for inspiration in sustainable, human-centered innovation.

Join us for an insightful episode featuring Cindy Crowninshield, RDN, LDN, Executive Event Director at Cambridge Healthtech Institute, as we explore how data-driven innovation is redefining the future of biotech and healthcare. With her unique vantage point at the helm of Bio-IT World—the leading global forum uniting life sciences, data science, and IT—Cindy offers an insider’s perspective on the groundbreaking ideas and technologies reshaping the industry.

In this conversation, we uncover how Bio-IT World has become a catalyst for collaboration across biopharma, healthcare, and technology, enabling researchers and organizations to harness AI, cloud computing, and advanced analytics to accelerate discovery and development. Cindy walks us through the major themes emerging from the event, from the rise of intelligent platforms and digital labs to the increasing role of data ecosystems in driving scientific and operational excellence.

We delve into real examples of companies transforming their R&D workflows through digital modernization, the strategies teams are adopting to stay competitive, and the opportunities arising as biotech and IT converge more closely than ever. Cindy also reflects on the evolving expectations of innovators and the new skill sets shaping the next generation of healthcare solutions.

Episode Highlights:
A deep look at the most significant trends shaping Bio-IT World
Insights into how AI, cloud, and analytics are revolutionizing drug development
Real-world stories of digital transformation across the life sciences sector
Perspectives on creating cross-disciplinary innovation networks and what the future holds

Whether you’re a biotech strategist, digital health leader, or data scientist at the forefront of innovation, this discussion offers valuable clarity on the technologies driving the next era of healthcare. Get ready to explore how computation, collaboration, and creativity are coming together to advance the future of medicine.